BioSpace News Archive

BIOLASE, Inc., the global leader in dental lasers, announced it has been invited to participate in the 11th Annual Benchmark Discovery One-on-One Investor Conference taking place December 1, 2022 in New York City.

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced the resubmission on November 9, 2022 of a Biologics License Application to the U.S. Food and Drug Administration for PRX–102 for the treatment of adult patients with Fabry disease.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update.

AstraZeneca and Merck (NYSE: MRK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of LYNPARZA in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented two posters at the 2022 meeting of the American College of Allergy, Asthma & Immunology in Louisville, Kentucky.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted its investigational new drug (“IND”) application for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjunct treatment of severe community-acquired bacterial pneumonia (“SCABP”).

Protalix BioTherapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided a business update on recent corporate and regulatory developments.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the Company will share preclinical data for FHD-609, a first-in-class, highly potent and selective degrader of BRD9, at the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting.

Investigators at Hospital for Special Surgery have discovered that at the time of total knee replacement, women have significantly increased levels of immune cells called mast cells in synovial tissue surrounding the knee joint than men.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that Health Canada has issued the Company a “No Objection Letter” to proceed with the Company’s trial using XPro1595 to treat mild Alzheimer’s Disease (AD) in Canada.